Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BIO-TECHNE (TECH) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to $155.5 million.

  • BIO-TECHNE's Shares Outstanding (Weighted Average) fell 1.92% to $155.5 million in Q3 2025 from the same period last year, while for Dec 2021 it was $157.2 million, marking a year-over-year increase of 1.78%. This contributed to the annual value of $156.8 million for FY2025, which is 0.52% down from last year.
  • Latest data reveals that BIO-TECHNE reported Shares Outstanding (Weighted Average) of $155.5 million as of Q3 2025, which was down 0.78% from $156.8 million recorded in Q2 2025.
  • BIO-TECHNE's Shares Outstanding (Weighted Average)'s 5-year high stood at $158.9 million during Q4 2024, with a 5-year trough of $155.2 million in Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $157.6 million, with a median of $157.6 million in 2024.
  • In the last 5 years, BIO-TECHNE's Shares Outstanding (Weighted Average) rose by 1.93% in 2021 and then decreased by 1.92% in 2025.
  • Quarterly analysis of 5 years shows BIO-TECHNE's Shares Outstanding (Weighted Average) stood at $157.2 million in 2021, then dropped by 0.13% to $157.0 million in 2022, then rose by 0.75% to $158.2 million in 2023, then rose by 0.47% to $158.9 million in 2024, then dropped by 1.92% to $155.5 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $155.5 million in Q3 2025, compared to $156.8 million in Q2 2025 and $158.1 million in Q1 2025.